WD-重复蛋白19在前列腺癌中的表达

Expression of WD-repeat protein 19 in prostate cancer

目的评估WD-重复蛋白19(WDR19)在前列腺癌、良性前列腺增生(BPH)和正常前列腺组织中的表达水平。方法收集前列腺癌组织标本187例、BPH组织标本15例和正常前列腺组织标本13例。此外,收集前列腺癌82例(按病情分为早期前列腺癌血清标本34份和进展期前列腺癌血清标本48份)、BPH患者血清标本103份。采用组织微阵列(TMA)技术结合WDR19免疫组织化学染色检测,对比免疫组织化学染色强度和免疫组织化学染色评分(SI)。采用Western印迹法检测血清WDR19表达水平。结果前列腺癌组织标本、BPH组织标本、正常前列腺组织标本的WDR19染色阴性率分别为8.6%、40.0%、38.5%,弱阳性率分别为44.9%、60.0%、53.8%,中阳性+强阳性率分别为46.5%、0、7.7%。前列腺癌组织标本的WDR19染色强度显著高于BPH组织标本和正常前列腺组织标本(P值均<0.01),而后两者间的差异无统计学意义(P>0.05)。前列腺癌组织标本SI≥3分的构成比为30.5%,显著高于BPH组织标本的13.3%和正常前列腺组织标本的7.5%(P值均<0.01)。早期前列腺癌血清标本的WDR19蛋白灰度值有高于BPH血清标本的趋势,但差异无统计学意义(P>0.05);进展期前列腺癌血清标本的WDR19蛋白灰度值显著高于BPH血清标本和早期前列腺癌血清标本(P值均<0.05)。结论 WDR19可能成为前列腺癌的候选标志物,其在前列腺癌的发生、发展过程中有一定的指示作用。

Objective To evaluate the expression of an androgen regulated protein （WDR19 WD-repeat protein 19） in prostate cancer, benign prostate hyperplasia（BPH） and healthy prostate. Methods One hundred and eighty-seven prostate cancer tissue samples （prostate cancer sample group）, 15 BPH tissue samples （BPH sample group） and 13 healthy prostate samples（healthy prostate sample group） were collected. Besides, serum samples were also collected in 82 prostate cancer patients （prostate cancer serum group, early prostate cancer sub-group 34 cases, advanced prostate cancer sub-group 48 cases） and 103 BPH patients （BPH serum group）. WDR19 expressions in tissue samples were analyzed via high-density tissue microarray （TMA） technique together with WDR19 immunohistochemical tests and their stain indexes （SI）. Serum WDR19 expressions were evaluated through Western blotting analysis. Results The WDR19 negative rates in prostate cancer sample group, BPH sample group and healthy prostate sample group were 8, 6%, 40.0% and 38.5%, respectively; weakly positive rates were 44.9%, 60.0% and 53.8%, respectively; and medium/strong positive rates were 46.5%, 0 and 7.7%, respectively. The staining intensity of WDR19 in prostate cancer sample group was significantly higher than BPH and healthy groups （P〈0.01）, while the latter two groups were not significantly different （P〉O. 05）. In the prostate cancer sample group, 30.5% samples were detected with SI≥3, significantly more than BPH and healthy prostate tissue groups （both P〈0. 01, respectively）. The densitornetry value of WDR19 protein in early prostate cancer sub-group higher than that in BPH serum group but with no significant difference （ P〉0. 05）, while that in advanced prostate cancer sub-group was significantly higher than those in BPH serum group and early prostate cancer sub-group （both P〈0. 05）. Conclusion WDR19 may be considered as a candidate marker for prostate cancer, and it is valuable in the indicatin the development and progression of prostate cancer.